Pharmacia Corp.

Pharmacia Corporation (commonly "Pharmacia Corp.") was a pharmaceutical and biotechnology company headquartered in Peapack, New Jersey. It was formed in April 2000 when Pharmacia & Upjohn merged with Monsanto (including its G.D. Searle drug unit), uniting Swedish Pharmacia AB (est. 1911), Upjohn (est. 1886, Kalamazoo, MI), and Searle. It traded publicly on the NYSE under "PHA" (also Stockholm). Pfizer acquired it on April 16, 2003, and it is now a wholly owned Pfizer subsidiary. Employee counts reported in the tens of thousands (roughly 43,000–59,000, varying by year and source); pre-acquisition revenue was reported around $14–18 billion.

Operations. Pharmacia sold prescription medicines, consumer healthcare, animal health, and diagnostics. Key products included Celebrex (celecoxib, co-promoted with Pfizer), Xalatan (latanoprost, glaucoma), Detrol/Detrusitol (overactive bladder), Genotropin (growth disorders), Camptosar (colorectal cancer), and Zyvox (linezolid, antibiotic). It spun off its Monsanto agricultural subsidiary in August 2002 to focus on pharmaceuticals. This is a large operating company, not a non-practicing entity.

Litigation posture. The single tracked case shows Pharmacia as defendant and zero cases as plaintiff. That reflects the specific dispute rather than an NPE posture: Pharmacia was the patent holder defending its glaucoma patents against a preemptive declaratory-judgment suit. Its only listed matter sits in the District of Delaware, not a plaintiff-friendly venue such as the Eastern District of Texas.

Notable case. Allergan, Inc. v. Pharmacia Corp., No. 01-141-SLR (D. Del.), was filed March 1, 2001. Allergan sought a declaration that Lumigan (bimatoprost) did not infringe Pharmacia's glaucoma-drug patents (including U.S. Patent 4,599,353) and that those patents were invalid; Columbia University appears as an additional defendant on a counterclaim tied to inventorship of the '353 patent. Xalatan had roughly $693 million in 2000 sales. The dispute was ultimately settled, with Pharmacia reporting a related one-time gain.